Table 2.

Reports Regarding Nivolumab-induced Hypopituitarism.

	Case 1 (17)	Case 2 (18)	Case 3 (19)	Case 4 (Present case)
Male/Female	male	male	male	male
Age	55	68	50	75
Primary disease	MM	MM	MM	NSCLC
Dosage (/kg)	2 mg/3 w	2 mg/3 w	2 mg/3 w	3 mg/2 w
Cycles of nivolumab therapy	4	ND	6	12
Time after nivolumab initiation	12 weeks	28 weeks	16 weeks	23 weeks
Radiographic pituitary enlargement	(-)	(-)	(+)	(-)
Hyponatremia	(-)	ND	(+)	(+)
Hypoglycemia	(-)	ND	(-)	(-)
Hypotension	(+)	ND	ND	(+)
Anterior pituitary dysfunction
TSH	(-)*	(-)	(+)	(-)
ACTH	(+)	(+)	(+)	(+)
LH/FSH	(-)*	(-)	(-)	(-)
GH	(-)*	(-)	(-)	(-)
PRL	(-)*	(-)	(+, elevated)**	(+, hyper-responsive)
Posterior pituitary dysfunction	(-)	(-)	(-)	(-)

MM: malignant melanoma, NSCLC: non-small-cell lung carcinoma, TSH: thyroid stimulating hormone, ACTH: adrenocorticotropic hormone, LH: luteinizing hormone, FSH: follicle-stimulating hormone, GH: growth hormone, PRL: prolactin, ND: not described,^* diagnosed by basal hormone levels,^** normal response in the stimulation test